Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Up0.62% Nasdaq Up0.56%

Halozyme Therapeutics, Inc. (HALO)

-NasdaqGS
7.46 Up 0.07(0.95%) 2:16PM EDT - Nasdaq Real Time Price
Get the big picture on all your investments.
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingDec 31, 2013Dec 31, 2012Dec 31, 2011
Total Revenue 54,799   42,325   56,086  
Cost of Revenue6,246  1,094  258  
Gross Profit 48,554   41,231   55,829  
Operating Expenses
Research Development96,640  70,044  57,563  
Selling General and Administrative32,348  24,812  18,104  
Non Recurring -   -   -  
Others -   -   -  
Total Operating Expenses -   -   -  
Operating Income or Loss (80,434) (53,625) (19,839)
Income from Continuing Operations
Total Other Income/Expenses Net229  73  69  
Earnings Before Interest And Taxes(80,204)(53,552)(19,770)
Interest Expense3,274   -   -  
Income Before Tax(83,479)(53,552)(19,770)
Income Tax Expense -   -   -  
Minority Interest -   -   -  
Net Income From Continuing Ops(83,479)(53,552)(19,770)
Non-recurring Events
Discontinued Operations -   -   -  
Extraordinary Items -   -   -  
Effect Of Accounting Changes -   -   -  
Other Items -   -   -  
Net Income (83,479) (53,552) (19,770)
Preferred Stock And Other Adjustments -   -   -  
Net Income Applicable To Common Shares (83,479) (53,552) (19,770)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.